Biomedical Plant Creates Bone from Fat Tissue and Blood

Using a sample of fat tissue and blood, a new facility creates stem cells specifically molded to the desired bone shape, and within one month the bone is ready for transplantation.

The new company, called Bonus Biogroup (Haifa, Israel), is developing proprietary technology for supplying bone regeneration tissues. Bone production will be undertaken in a new facility, under construction in the Haifa (Israel) Scientific Industries Center, slated for completion by June 2013. Once completed, the 750-square-meter center will be comprised of three divisions: a production center for bone implants, a research and development wing, and administrative headquarters.


Cultured from the patient's own cells, the bone regenerative methodology is a powerful tool for treating a variety of bone and joints diseases, without running the risk of tissue rejections and surgery failures. In addition, the technology makes it possible to produce the matched bone tissue in a precise, three dimensional (3D) high-density bone graft predesigned, spatial architecture; this leads to bone transplant available on demand which is safer and less expensive. Another unique aspect of the company’s technology is the proprietary bioreactor cell-matrix hybrid bone culturing technology to provide cellular-based bone replacement prosthetics.

The generated bone is intended to replace current gold standard autologous bone grafting procedure, which has several major handicaps. In many cases, the amount of autologous bone needed for the bone graft is not available for effective treatments; the existing procedure incurs donor morbidity and reduced graft strength; and the procedure is associated with chronic pain, discomfort, and mobility problems. Moreover, the autologous bone grafts cannot be accurately shaped to fit the missing bone, damaging the healing process, and leaving unaesthetic cavities in the treated patients.

“Bonus BioGroup intends to develop its products, perform clinical trials, and gain regulatory authorities approvals for the use of its bone grafts. The designed bone grafts will address a very substantial portion of the regeneration medicine market, and thus represent a highly attractive market opportunity,” said Shai Meretzki, CEO of Bonus Biogroup. “Construction of the production center is a critical stage in the implementation of the company's unique technology.”


Related Links:
Bonus Biogroup